MedGenome has introduced the CNS Tumor Methylation Classifier Test, a pioneering diagnostic tool in India capable of distinguishing and categorizing more than 90 types of brain and central nervous system (CNS) tumors into precise subtypes. This cutting-edge test provides valuable insights for doctors to make informed treatment decisions. Unveiled at a precision oncology symposium in Mumbai, the test was developed in collaboration with Illumina, a global leader in DNA sequencing and life sciences technologies. Brain and CNS tumors pose significant diagnostic challenges due to their complexity. MedGenome’s innovative test complements traditional methods by analyzing the entire genome, identifying molecular alterations, and predicting treatment responses based on DNA methylation profiling—a technique that examines chemical modifications across the genome to create a distinctive tumor profile. By comparing this profile to an extensive global reference database, the test accurately identifies the tumor type, facilitating tailored treatment strategies. Even in rare or challenging cases, the test has demonstrated high efficiency, offering comprehensive support for precise treatment decisions and personalized care.
The CEO of MedGenome, VL Ramprasad, PhD, emphasized the importance of individualized cancer treatment, highlighting the unique behavior of tumors even within the same diagnosis. By leveraging advanced technologies like whole genome methylation profiling, MedGenome aims to enable early diagnosis and targeted disease management through genetic and molecular insights. The company’s focus on science and innovation is evident in the development of this groundbreaking genomic test, which underscores its commitment to providing science-backed and affordable solutions for omics research on a global scale. The CNS Tumor Methylation Classifier Test by MedGenome adheres to the World Health Organization’s 2021 guidelines for CNS tumor classification. With a turnaround time of 21 days, the test includes WHO grade assignment, genome-wide copy number profiling, and detection of key gene alterations in line with international best practices.
In a healthcare landscape where personalized medicine is gaining momentum, MedGenome’s CNS Tumor Methylation Classifier Test represents a significant advancement in precision oncology. By offering a comprehensive approach to brain tumor classification, this innovative test equips healthcare professionals with the necessary tools to make optimal treatment decisions tailored to each patient’s unique molecular profile. The ability to accurately categorize and subtype a wide range of brain and CNS tumors enables more targeted and effective treatment strategies, ultimately improving patient outcomes and quality of care. MedGenome’s collaboration with Illumina further enhances the credibility and reliability of the test, leveraging cutting-edge DNA sequencing technologies to provide accurate and timely results for oncologists, neuro-onco surgeons, pathologists, researchers, and doctoral students.
Overall, MedGenome’s launch of the CNS Tumor Methylation Classifier Test marks a significant milestone in the field of precision oncology in India. With its ability to differentiate over 90 classes of brain and CNS tumors and provide accurate subtyping, this test has the potential to revolutionize the way these complex cancers are diagnosed and treated. By incorporating advanced genomic technologies and global best practices, MedGenome is at the forefront of driving innovation in cancer diagnostics and personalized medicine. The successful implementation of this test underscores the company’s commitment to advancing healthcare through cutting-edge research and technology, ultimately benefiting patients and healthcare providers alike.
- MedGenome’s CNS Tumor Methylation Classifier Test offers a revolutionary approach to brain tumor classification, enabling precise subtyping of over 90 classes of tumors.
- By leveraging DNA methylation profiling and global reference databases, the test provides valuable insights for tailored treatment decisions in cases that are rare or challenging to classify accurately.
- Aligned with international guidelines and best practices, the test delivers results within 21 days, facilitating timely and informed treatment planning for oncologists, neuro-onco surgeons, and pathologists.
- MedGenome’s collaboration with Illumina underscores the credibility and reliability of the test, highlighting the company’s commitment to driving innovation in precision oncology.
Read more on pharmabiz.com